Adam Feldman, MD
Urology · Boston, MANPI 1457342636
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $49,860 of the $73,646 with a category attached, or 67.7%. 13 manufacturers reported payments, led by Urogen Pharma, Inc. at 44.0% of the total. 2025 is the largest year on record at $19,437, 2.2 times the $8,776 reported in 2019. Among urology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $909.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$32K
- Olympus Corporation Of The Americas$16K
- Johnson & Johnson$9K
- Ferring Pharmaceuticals Inc.$7K
- Progenics Pharmaceuticals, Inc.$4K
- Gyrus ACMI, Inc.$2K
- plus $3K from 7 others
Across 21 payments — averaging $7838.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Progenics Pharmaceuticals, Inc.$139K
- Urogen Pharma, Inc.$26K
What the payments were for
- Consulting fees$49,86068%
- Speaking & faculty fees$3,4285%
- Travel & lodging$3,1244%
- Food & beverage$2,5273%
- Education$14,70720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 16 | $32,437 |
| Olympus Corporation Of The Americas | 31 | $15,501 |
| Johnson & Johnson | 10 | $9,157 |
| Ferring Pharmaceuticals Inc. | 5 | $7,334 |
| Progenics Pharmaceuticals, Inc. | 3 | $3,771 |
| Gyrus ACMI, Inc. | 3 | $2,430 |
| Olympus America Inc. | 1 | $1,080 |
| Olympus Corporation | 2 | $990 |
| Blue Earth Diagnostics | 1 | $255 |
| Genentech USA, Inc. | 1 | $237 |
| Astellas Pharma US Inc | 3 | $214 |
| Janssen Scientific Affairs, LLC | 4 | $184 |
| Genentech, Inc. | 1 | $57 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JELMYTO$19,574
- Olympus Cystoscopes$10,824
- Olympus Resection Disposables$10,824
- Olympus Laser Devices$9,924
- HD CAMERA HEAD$4,320
- CYSTO-NEPHRO VIDEOSCOPE$4,320
- OES CYSTONEPHROFIBERSCOPE$4,320
- PYLARIFY$3,715
- ZUSDURI$2,888
- Erleada$1,253
- Olympus Cysto-Resection$900
- POSLUMA$255
How this compares
$73,646 in reported general payments places this provider in the 95th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Solifenacin Succinate | 20 | $617 |
| Finasteride | 26 | $371 |
| Tamsulosin Hcl | 11 | $231 |
Paid to pharmacies, not to this prescriber.
Other urology in Boston
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- Stephen DretlerBoston$298K
- Tony LuongoBoston$265K
- Ricardo MunarrizBoston$118K
- Mehrdad AlemozaffarBoston$95K
- Adam KibelBoston$92K
- Ruslan KoretsBoston$86K
- William BoysenBoston$56K
- Shahin TabatabaeiBoston$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.